TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Most patients with colorectal cancer die as a result of the disease spreading to other organs. However, no prevalent mutations have been associated with metastatic colorectal cancers. Instead, particular features of the tumour microenvironment, such as lack of T-cell infiltration, low type 1 T-helper cell (T H 1) activity and reduced immune cytotoxicity or increased TGFβ levels predict adverse outcomes in patients with colorectal cancer. Here we analyse the interplay between genetic alterations and the tumour microenvironment by crossing mice bearing conditional alleles of four main colorectal cancer mutations in intestinal stem cells. Quadruple-mutant mice developed metastatic intestinal tumours that display key hallmarks of human microsatellite-stable colorectal cancers, including low mutational burden, T-cell exclusion and TGFβ-activated stroma. Inhibition of the PD-1-PD-L1 immune checkpoint provoked a limited response in this model system. By contrast, inhibition of TGFβ unleashed a potent and enduring cytotoxic T-cell response against tumour cells that prevented metastasis. In mice with progressive liver metastatic disease, blockade of TGFβ signalling rendered tumours susceptible to anti-PD-1-PD-L1 therapy. Our data show that increased TGFβ in the tumour microenvironment represents a primary mechanism of immune evasion that promotes T-cell exclusion and blocks acquisition of the T H 1-effector phenotype. Immunotherapies directed against TGFβ signalling may therefore have broad applications in treating patients with advanced colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Blockade of the TGFβ signaling pathway promotes enough T cell infiltration to make tumors sensitive to PD-1 therapy [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“Cell analysis of human and mouse CRC specimens showed that CAF is a major contributor to TGF-β production [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“It has been demonstrated in a variety of tumor models, including CRC models, that activation of CAF may induce PD-1 and CTLA-4 expression on relevant immune cells, which leads to tumor insensitivity to immunotherapy or recurrence [39,304,305,306].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“A landmark study from 2018 demonstrated that TGF-β contributes to immune exclusion in colorectal liver metastasis and that inhibition of the TGF-β receptor 1 using the drug galunisertib enhanced tumorous infiltration with T cells, inhibited outgrowth of liver metastases and synergised with anti-PD-L1 therapy to eradicate established lesions.161”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [161]
In the citing paper
“leading to the proposition that combined TGFβ targeting and immune checkpoint blockade may represent an attractive therapeutic strategy for CMS4 colorectal cancer (34).”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [34]
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Data Analysis Using Regression and Multilevel/Hierarchical Models
Gelman, A., & Hill, J. (2006) · doi:10.1017/cbo9780511790942 · Cited by 13,597
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cited by
Items 401–500 of 1,002
Allies or Enemies—The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment
Haas, L., & Obenauf, A. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02746 · Cited by 89
“In addition, secreted factors can also directly inhibit the antitumor activity of DCs, such as TGF-β, which can inhibit antigen uptake in vitro and it was shown that inhibiting TGF-β signaling synergizes with immunotherapy in pre-clinical mouse models (15, 37, 38).”
BackgroundFuture Challenges in Cancer Resistance to Immunotherapy
van Elsas, M. J., van Hall, T., & van der Burg, S. H. (2020) · Cancers · doi:10.3390/cancers12040935 · Cited by 74
Targeting transforming growth factor-β signaling for enhanced cancer chemotherapy
Chen, J., Ding, Z., Li, S., Liu, S., Xiao, C., Li, Z., Zhang, B., Chen, X., & Yang, X. (2020) · Theranostics · doi:10.7150/thno.51383 · Cited by 82
Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression
van den Bulk, J., de Miranda, N. F. C. C., & ten Dijke, P. (2021) · Clinical Science · doi:10.1042/cs20201236 · Cited by 82
The importance of being CAFs (in cancer resistance to targeted therapies)
Rizzolio, S., Giordano, S., & Corso, S. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02524-w · Cited by 82
“In this context, several authors reported that CAFs can promote an immunosuppressive environment, both directly, through the secretion of several chemokines or other negative immune-regulators [17, 18], and indirectly, by regulating the stiffness of the ECM, which decreases immune cell infiltration or immune cell extr…”
Li, N., Rodriguez, J. L., Yin, Y., Logun, M. T., Zhang, L., Yu, S., Hicks, K., Zhang, J. V., Zhang, L., Xie, C., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.020 · Cited by 84
Immunomodulation of Tumor Vessels: It Takes Two to Tango
Johansson-Percival, A., He, B., & Ganss, R. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.08.001 · Cited by 73
Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
Ghiringhelli, F., & Fumet, J.-D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01816 · Cited by 84
“Inhibition of TGFβ using a pharmacological inhibitor or a mAb promotes T cell recruitment to the tumor bed and efficacy of checkpoint inhibitors (22).”
MethodRole of myeloid cells in the immunosuppressive microenvironment in gliomas
Locarno, C. V., Simonelli, M., Carenza, C., Capucetti, A., Stanzani, E., Lorenzi, E., Persico, P., Bella, S. D., Passoni, L., Mavilio, D., et al. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.10.002 · Cited by 79
Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 79
Malenica, I., Adam, J., Corgnac, S., Mezquita, L., Auclin, É., Damei, I., Grynszpan, L., Gros, G., de Montpréville, V., Planchard, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25322-y · Cited by 84
Bu, M. T., Chandrasekhar, P., Ding, L., & Hugo, W. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108211 · Cited by 84
“…Dijke, 2009; Nishida, Yano, Nishida, Kamura, & Kojiro, 2006; Sánchez-Elsner et al., 2001), and immunosuppression (Batlle & Massagué, 2019; Chakravarthy, Khan, Bensler, Bose, & De Carvalho, 2018; Derynck, Turley, & Akhurst, 2021; Jiang et al., 2018; Mariathasan et al., 2018; Tauriello et al., 2018).”
Küçükköse, E., Heesters, B. A., Villaudy, J., Verheem, A., Cercel, M. G., van Hal, S., Boj, S. F., Rinkes, I. H. M. B., Punt, C. J. A., Roodhart, J. M. L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005345 · Cited by 78
Control of Dendritic Cell Function Within the Tumour Microenvironment
Hari‐Gupta, Y., Khanom, A., & Acton, S. E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.733800 · Cited by 78
Jung, I.-Y., Noguera-Ortega, E., Bartoszek, R. L., Collins, S. M., Williams, E. F., Suhoski, M. M., Jadlowsky, J. K., Plesa, G., Siegel, D. L., Chew, A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101053 · Cited by 84
Guillebon, É. D., Dardenne, A., Saldmann, A., Séguier, S., Tran, T., Paolini, L., Lebbé, C., & Tartour, É. (2020) · International Journal of Cancer · doi:10.1002/ijc.32889 · Cited by 78
Tumor accomplice: T cell exhaustion induced by chronic inflammation
Fang, L., Liu, K., Liu, C., Wang, X., Ma, W., Xu, W., Wu, J., & Sun, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.979116 · Cited by 77
TGF-β in the microenvironment induces a physiologically occurring immune-suppressive senescent state
Matsuda, S., Revandkar, A., Dubash, T. D., Ravi, A., Wittner, B. S., Lin, M., Morris, R. T., Burr, R., Guo, H., Seeger, K., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112129 · Cited by 84
Revisiting the role of cancer-associated fibroblasts in tumor microenvironment
Lan, X., Li, W., Zhao, K., Wang, J., Li, S., & Hai, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1582532 · Cited by 84
Dodagatta-Marri, E., Ma, H.-Y., Liang, B., Li, J., Meyer, D. S., Sun, K.-H., Ren, X., Zivak, B., Rosenblum, M. D., Headley, M. B., et al. (2020) · doi:10.1101/2020.05.14.084913 · Cited by 70
“Previous studies have shown that inhibition of TGF-β signaling can enhance responses to checkpoint inhibitors (Dodagatta-Marri et al., 2019; Mariathasan et al., 2018; Tauriello et al., 2018).”
BackgroundWang, Q., Zhuang, X., Sriwastva, M. K., Mu, J., Teng, Y., Deng, Z., Zhang, L., Sundaram, K., Kumar, A., Miller, D. M., et al. (2018) · Theranostics · doi:10.7150/thno.27608 · Cited by 76
Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF-β pathway
Wang, Q., Cai, J., Fang, C., Yang, C., Zhou, J., Tan, Y., Wang, Y., Li, Y., Meng, X., Zhao, K., et al. (2018) · Theranostics · doi:10.7150/thno.26550 · Cited by 79
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Merz, V., Gaule, M., Zecchetto, C., Cavaliere, A., Casalino, S., Pesoni, C., Contarelli, S., Sabbadini, F., Bertolini, M., Mangiameli, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638360 · Cited by 70
“In immune-excluded colorectal cancer models the inhibition of TGF-b promoted antitumorigenic immune infiltration, restoring sensitivity to PD-L1/ PD-1 blockade (118).”
BackgroundSheng, W., Liu, Y., Chakraborty, D., Debo, B. M., & Shi, Y. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0017 · Cited by 79
Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer
Roane, B. M., Arend, R. C., & Birrer, M. J. (2019) · Cancers · doi:10.3390/cancers11050668 · Cited by 74
“Anti-PD-L1 therapy yielded a limited response in the model; however, inhibition of TGF-β with a small molecule inhibitor produced a robust cytotoxic T-cell response preventing metastasis and increasing susceptibility to anti-PD-L1 therapy [93].”
BackgroundTGFβ blocks IFNα/β release and tumor rejection in spontaneous mammary tumors
Guérin, M. V., Régnier, F., Feuillet, V., Vimeux, L., Weiss, J. M., Bismuth, G., Altan-Bonnet, G. Y., Guilbert, T., Thoreau, M., Finisguerra, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11998-w · Cited by 77
Jung, S. Y., Hwang, S., Clarke, J. M., Bauer, T. M., Keedy, V. L., Lee, H., Park, N., Kim, S.-J., & Lee, J. I. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00835-y · Cited by 69
Therapeutic Targeting of the Colorectal Tumor Stroma
Fridman, W. H., Miller, I. S., Sautès‐Fridman, C., & Byrne, A. T. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.09.045 · Cited by 79
Advances in colon cancer research: in vitro and animal models
Lannagan, T. R. M., Jackstadt, R., Leedham, S. J., & Sansom, O. J. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.12.003 · Cited by 80
“Importantly, these GEMMs and organoid models were proven to recapitulate characteristics of human cancers and could be stratified into different CMS [40 ,43,44].”
BackgroundMethodNadal, E., Saleh, M. N., Ponce-Aix, S., Ochoa-de-Olza, M., Patel, S. P., Antonia, S. J., Zhao, Y., Gueorguieva, I., Man, M. Z., Estrem, S. T., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11153-1 · Cited by 78
“Inhibition of TGF-β releases a cytotoxic T-cell response against tumor cells and allows immune cells to infiltrate the tumor [24].”
BackgroundShidal, C., Singh, N. P., Nagarkatti, P. S., & Nagarkatti, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2659 · Cited by 72
The Tumor Microenvironment in Colorectal Cancer Therapy
Pedrosa, L., Esposito, F., Thomson, T. M., & Maurel, J. (2019) · Cancers · doi:10.3390/cancers11081172 · Cited by 69
Intratumor CMS heterogeneity impacts patient prognosis in localized colon cancer
Marisa, L., Blum, Y., Taieb, J., Ayadi, M., Pilati, C., Le Malicot, K., Lepage, C., Salazar, R., Aust, D., Duval, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0529 · Cited by 68
“CMS1 tumors, it is tempting to speculate that the CMS4 component releases TGFb, favoring immune escape of the highly genetically instable CMS1 component (35).”
BackgroundSensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
Zemek, R. M., Chin, W. L., Nowak, A. K., Millward, M., Lake, R., & Lesterhuis, W. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00223 · Cited by 75
“The immunosuppressor TGF-β1 is promoted by overexpression of HIF-1α in tumor hypoxia, which fosters exclusion of T lymphocytes (71, 112).”
BackgroundImmunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses
Groeneveldt, C., van Hall, T., van der Burg, S. H., ten Dijke, P., & van Montfoort, N. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.003 · Cited by 73
TGF-β in Cancer: Metabolic Driver of the Tolerogenic Crosstalk in the Tumor Microenvironment
Angioni, R., Sánchez‐Rodríguez, R., Viola, A., & Molon, B. (2021) · Cancers · doi:10.3390/cancers13030401 · Cited by 81
“In addition, pre-clinical studies highlighted a strong association between TGF-β activation and unresponsiveness to antiPDL1 therapy, further suggesting that combined approaches targeting TGF-β pathway and checkpoint blockade might represent a promising strategy for the treatment of nonresponsive tumors [111,112].”
BackgroundThe proprotein convertase furin in cancer: more than an oncogene
He, Z., Khatib, A., & Creemers, J. W. M. (2022) · Oncogene · doi:10.1038/s41388-021-02175-9 · Cited by 77
“The reduced Furin expression mainly inhibits TGFβ1 production in tumor cells and contributes to initiating anti-tumoral responses of T-cell activation [127].”
BackgroundTGF-β and Cancer Immunotherapy
Maruyama, T., Chen, W., & Shibata, H. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00966 · Cited by 73
WNT and β-Catenin in Cancer: Genes and Therapy
Jackstadt, R., Hodder, M. C., & Sansom, O. J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033628 · Cited by 64
“The striking results of immune checkpoint inhibition (ICI) in recent years has generated an increased interest in the tumor immune microenvironment (TIME) of solid cancers (Binnewies et al. 2018, Topalian et al. 2016).”
BackgroundCancer-Associated Fibroblasts and T Cells: From Mechanisms to Outcomes
Baker, A. T., Abuwarwar, M. H., Poly, L., Wilkins, S., & Fletcher, A. L. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001203 · Cited by 67
“(47) have also shown that cotreatment of PD-L1 and TGF-b inhibitors in a genetically recon-”
BackgroundReverting Immune Suppression to Enhance Cancer Immunotherapy
Guerrouahen, B. S., Maccalli, C., Cugno, C., Rutella, S., & Akporiaye, E. T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01554 · Cited by 77
The unique immune microenvironment of liver metastases: Challenges and opportunities
Ciner, A., Jones, K. I., Muschel, R. J., & Brodt, P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.003 · Cited by 79
Organoids and Colorectal Cancer
Barbáchano, A., Fernández‐Barral, A., Bustamante‐Madrid, P., Prieto, I., Rodríguez-Salas, N., Larriba, M. J., & Múñoz, A. (2021) · Cancers · doi:10.3390/cancers13112657 · Cited by 82
Stromal Cells in the Pathogenesis of Inflammatory Bowel Disease
Barnhoorn, M. C., Hakuno, S. K., Bruckner, R. S., Rogler, G., Hawinkels, L. J. A. C., & Scharl, M. M. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa009 · Cited by 74
Shklovskaya, E., & Rizos, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197139 · Cited by 73
Gao, Y., Wang, H., Li, H., Ye, X., Xia, Y., Yuan, S., Lu, J., Xie, X., Wang, L., & Zhang, J. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1936758 · Cited by 75
“As reported in a previous study, inhibition of EMT- and TGFβ-related pathways could increase the trafficking of cytotoxic T-cells against tumor cells, thus preventing metastasis.(30,31) In addition, we found that patients with high m1AScore had higher TNM stages and lymphatic invasion, which indicated a poor prognosis.”
ResultPeuker, K., Strigli, A., Tauriello, D. V. F., Hendricks, A., Schönfels, W. V., Burmeister, G., Brosch, M., Herrmann, A., Krüger, S., Nitsche, J., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.008 · Cited by 72
Self-citationCancer immune exclusion: breaking the barricade for a successful immunotherapy
Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, R. I. C., & Schillaci, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135456 · Cited by 79
Su, Y., Wang, T., Su, Y., Li, M., Zhou, J., Zhang, W., & Wang, W. (2019) · Materials Horizons · doi:10.1039/c9mh01068h · Cited by 65
Immune-resistant mechanisms in cancer immunotherapy
Kawakami, Y., Ohta, S., Sayem, M. A., Tsukamoto, N., & Yaguchi, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01611-x · Cited by 69
Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy
Kumar, A., Chamoto, K., Chowdhury, P. S., & Honjo, T. (2020) · eLife · doi:10.7554/elife.52330 · Cited by 66
“…factor β (TGF-β), interleukin-10 (IL-10), adenosine, granulocyte-macrophage colony-stimulating factor (GM-CSF), prostaglandin E2 (PGE2), and L-Kynurenine (Artis & Spits, 2015; DeNardo & Ruffell, 2019; Facciabene, Motz, & Coukos, 2012; Sarvaria, Madrigal, & Saudemont, 2017; Tauriello et al., 2018).”
BackgroundCAR T Cell Locomotion in Solid Tumor Microenvironment
Nguyen, D., Ogando‐Rivas, E., Liu, R., Wang, T., Rubin, J. A., Jin, L., Tao, H., Sawyer, W. W., Méndez‐Gómez, H. R., Cascio, M., et al. (2022) · Cells · doi:10.3390/cells11121974 · Cited by 69
“Tregs within the TME can act antagonistically to effector T cells by secreting a number of cytokines (e.g., IL10, IL35, TGFβ), upregulating cytotoxic T lymphocyte antigen 4 (CTLA4), and inhibiting CD80/CD86 co-stimulatory pathways, by competing for binding of IL-2 [163].”
BackgroundInfluentialLicaj, M., Mhaidly, R., Kieffer, Y., Croizer, H., Bonneau, C., Meng, A., Djerroudi, L., Mujangi-Ebeka, K., Hocine, H. R., Bourachot, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45595-3 · Cited by 72
ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-β signalling
Pinho, A. V., Van Bulck, M., Chantrill, L., Arshi, M., Sklyarova, T., Herrmann, D., Vennin, C., Gallego-Ortega, D., Mawson, A., Giry-Laterriere, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07497-z · Cited by 64
Strategies for developing and optimizing cancer vaccines
Maeng, H. M., & Berzofsky, J. A. (2019) · F1000Research · doi:10.12688/f1000research.18693.1 · Cited by 68
van den Bulk, J., Verdegaal, E. M. E., Ruano, D., Ijsselsteijn, M. E., Visser, M., van der Breggen, R., Duhen, T., van der Ploeg, M., de Vries, N. L., Oosting, J., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0697-8 · Cited by 63
Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion
Hilmi, M., Nicolle, R., Bousquet, C., & Neuzillet, C. (2020) · Cancers · doi:10.3390/cancers12102969 · Cited by 69
Contribution of Epithelial Plasticity to Therapy Resistance
Santamaría, P. G., Moreno‐Bueno, G., & Cano, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050676 · Cited by 69
Bertucci, F., Boudin, L., Finetti, P., Berckelaer, C. V., van Dam, P. A., Dirix, L. Y., Viens, P., Gonçalvès, A., Ueno, N. T., Laere, S. V., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1929724 · Cited by 64
Fujiwara, Y., Mittra, A., Naqash, A. R., & Takebe, N. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.11 · Cited by 87
Martinez-Ordoñez, A., Duran, A., Ruiz-Martinez, M., Cid-Diaz, T., Zhang, X., Han, Q., Kinoshita, H., Muta, Y., Linares, J. F., Kasashima, H., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.11.016 · Cited by 60
Targeting tumor-infiltrating tregs for improved antitumor responses
Qin, D., Zhang, Y., Shu, P., Lei, Y., Li, X., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1325946 · Cited by 77
Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
McCloskey, C. W., Rodriguez, G. M., Galpin, K. J. C., & Vanderhyden, B. C. (2018) · Cancers · doi:10.3390/cancers10080244 · Cited by 67
“In a model of colorectal cancer, Tauriello and colleagues recently showed that TGF-β inhibition prevents tumor metastasis by increasing cytotoxic T-cell responses [53].”
BackgroundPatel, S. A., Rodrigues, P., Wesolowski, L., & Vanharanta, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01127-6 · Cited by 61
Epithelial-to-Mesenchymal Transition in the Light of Plasticity and Hybrid E/M States
Bornes, L., Belthier, G., & van Rheenen, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112403 · Cited by 65
Lin, Y., Pan, X., Zhao, L., Yang, C., Zhang, Z., Wang, B., Gao, Z., Jiang, K., Ye, Y., Wang, S., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00249-x · Cited by 68
CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors
Qin, V. M., Haynes, N. M., D’Souza, C., Neeson, P. J., & Zhu, J. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.813832 · Cited by 69
“Neutralizing the TGF-b signal in the TME has been shown to unleash potent T cell responses, thereby rendering tumors susceptible to immunotherapy, including CAR-T cell treatment (66, 67).”
BackgroundBacterial inhibition of Fas-mediated killing promotes neuroinvasion and persistence
Maudet, C., Kheloufi, M., Levallois, S., Gaillard, J., Huang, L., Gaultier, C., Tsai, Y.-H., Disson, O., & Lecuit, M. (2022) · Nature · doi:10.1038/s41586-022-04505-7 · Cited by 67
Huang, S., Ding, D., Lan, T., He, G., Ren, J., Liang, R., Zhong, H., Chen, G., Lu, X. M., Shuai, X., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.04.001 · Cited by 64
Henriques, A. R., Salvany, M., Nieto, P., Palomo‐Ponce, S., Sevillano, M., Hernando‐Momblona, X., Guerra, E. M., Llanses, M., Haak, E., Nieto, J. C., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02380-2 · Cited by 70
Self-citationNakanishi, Y., Duran, A., L’Hermitte, A., Shelton, P. M., Nakanishi, N., Reina-Campos, M., Huang, J., Soldevila, F., Baaten, B. J. G., Tauriello, D. V. F., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.013 · Cited by 60
Self-citationA new therapeutic target: the CD69-Myl9 system in immune responses
Kimura, M. Y., Koyama‐Nasu, R., Yagi, R., & Nakayama, T. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00734-7 · Cited by 64
Lima, J. D. C. C., Simoes, E., de Castro, G. S., Morais, M., de Matos‐Neto, E. M., Alves, M. J., Neto, N. I. P., Figuerêdo, R. G., Zorn, T. M. T., Felipe-Silva, A., et al. (2019) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12441 · Cited by 67
“(2018) showed that increased content of TGF-β in the tumour micro-environment could represent a primary mechanism for immune evasion.(67)We also report lower levels of tumour suppressor p53 in CC, when compared with WSC.”
BackgroundResultGuo, W., Gao, H., Li, H., Ge, S., Zhang, F., Wang, L., Shi, H., & Han, A. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c06001 · Cited by 63
Context-dependent TGFβ family signalling in cell fate regulation
Richardson, L., Wilcockson, S. G., Guglielmi, L., & Hill, C. S. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00638-3 · Cited by 72
Mandal, K., Barik, G. K., & Santra, M. K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02400-z · Cited by 78
Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches
Tintelnot, J., & Stein, A. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i29.3920 · Cited by 64
Macrophage ABHD5 Suppresses NFκB-Dependent Matrix Metalloproteinase Expression and Cancer Metastasis
Shang, S., Ji, X., Zhang, L., Chen, J., Li, C., Shi, R., Xiang, W., Kang, X., Zhang, D., Yang, F., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1059 · Cited by 62
Jiang, Y., Liang, X., Han, Z., Wang, W., Xi, S., Li, T., Chen, C., Yuan, Q., Li, N., Yu, J., et al. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00065-0 · Cited by 58
Filliol, A., & Schwabe, R. F. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1685539 · Cited by 58
JNK in Tumor Microenvironment: Present Findings and Challenges in Clinical Translation
Tam, S. Y., & Law, H. (2021) · Cancers · doi:10.3390/cancers13092196 · Cited by 67
“In CRC metastasis, TGF-β took an important role in immune evasion [73] and the increased TGF-β level predicted poor prognosis in CRC patients [74].”
BackgroundGlycosylation of Immune Receptors in Cancer
Sun, R., Kim, A. M. J., & Lim, S. (2021) · Cells · doi:10.3390/cells10051100 · Cited by 65
He, Y., Fang, Y., Zhang, M., Zhao, Y., Tu, B., Shi, M., Muhitdinov, B. I., Asrorov, A. M., Xu, Q., & Huang, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.022 · Cited by 60
Busenhart, P., Montalban‐Arques, A., Katkeviciutė, E., Morsy, Y., Passen, C. V., Hering, L., Atrott, K., Lang, S., Garzon, J. F. G., Naschberger, E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003465 · Cited by 61
Bacteria‐Based Backpacks to Enhance Adoptive Macrophage Transfer against Solid Tumors
An, J., Han, Z., Qin, Y., Li, C., He, J., & Zhang, X. (2023) · Advanced Materials · doi:10.1002/adma.202305384 · Cited by 63
Ye, J., Lin, Y., Liao, Z., Gao, X., Lu, C., Lu, L., Huang, J., Huang, X., Huang, S., Yu, H., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00752-1 · Cited by 55
“…, transforming growth factor beta 1 (TGFB1) , interleukin 1 receptor antagonist (IL1RN) ) and anti-in fl ammatory factors (tumor necrosis factor receptor superfamily member 1b (TNFRSF1B) ) 42 for the exertion of phagocytosis, immunosuppression,andtissueremodelinglikingasthefunctionsofM2-TAMs 43,44 .”
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 78
Greco, R., Qu, H., Qu, H., Theilhaber, J., Shapiro, G., Gregory, R., Winter, C., Malkova, N., Sun, F., Jaworski, J., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1811605 · Cited by 58
Pilones, K. A., Hensler, M., Daviaud, C., Kraynak, J., Fucikova, J. P., Galluzzi, L., Demaria, S., & Formenti, S. C. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1830524 · Cited by 67
DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers
Bañobre, J. R., & Goel, A. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.11.071 · Cited by 62
The outstanding antitumor capacity of CD4+ T helper lymphocytes
Li, T., Wu, B., Yang, T., Zhang, L., & Jin, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188439 · Cited by 63
Yen, Y., Chien, M., Wu, P., Ho, C.-C., Ho, C.-T., Huang, K. C., Chiang, S., Chao, K., Chen, W. T., & Hung, S. (2021) · Nature Communications · doi:10.1038/s41467-021-27620-x · Cited by 64
Mezawa, Y., & Orimo, A. (2021) · FEBS Journal · doi:10.1111/febs.15851 · Cited by 61
TGF-β Modulated Pathways in Colorectal Cancer: New Potential Therapeutic Opportunities
Fasano, M., Pirozzi, M., Miceli, C. C., Cocule, M., Caraglia, M., Boccellino, M., Vitale, P., Falco, V. D., Farese, S., Zotta, A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137400 · Cited by 69
“Tauriello et al. [88] showed that higher TGF-β levels in the TME cause T cell exhaustion and inhibit the Th1-effector phenotype, leading to an immunologically cold environment and poor prognosis.”
BackgroundPrognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 57
Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
Uckun, F. M. (2021) · Cancers · doi:10.3390/cancers13092018 · Cited by 61
Ni, Y., Soliman, A., Joehlin-Price, A., Rose, P. G., Vlad, A., Edwards, R. P., & Mahdi, H. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00242-8 · Cited by 55
Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice
Ragusa, S., Prat-Luri, B., González-Loyola, A., Nassiri, S., Squadrito, M. L., Guichard, A., Cavin, S., Gjorevski, N., Barras, D., Marra, G., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129558 · Cited by 56
“…Bianchi, 8 Laureline Wetterwald, 1,2 Jaeryung Kim, 1,2 Guillermo Oliver, 9 Mauro Delorenzi, 1,2,3 Michele De Palma, 4 and Tatiana V. Petrova recently been shown to increase sensitivity to PD-1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoint blockade in genetic models of CRC (14).”
InfluentialShima, T., Shimoda, M., Shigenobu, T., Ohtsuka, T., Nishimura, T., Emoto, K., Hayashi, Y., Iwasaki, T., Abe, T., Asamura, H., et al. (2019) · Cancer Science · doi:10.1111/cas.14272 · Cited by 63
Wang, H., Chen, M., Sang, X., You, X., Wang, Y., Paterson, I. C., Hong, W., & Yang, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112154 · Cited by 59
Metadata
- Authors
- Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., Byrom, D., Matarin, J. A., Calon, A., Rivas, E. I., Nebreda, A. R., Riera, A., Attolini, C. S.-O., & Batlle, E.
- Affiliations
- Institute for Research in Biomedicine (ES)
- Universitat Autònoma de Barcelona (ES)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Batlle, Eduard
- ORCID
- Venue
- Nature
- Published
- 2018-02
- Volume
- 554
- Issue
- 7693
- Pages
- 538-543
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2788975052
- Cited by
- 1,851
- References
- 43
- Citations by year
- 2026: 193 · 2025: 186 · 2024: 159 · 2023: 211 · 2022: 280 · 2021: 305 · 2020: 247 · 2019: 176 · 2018: 94
- FWCI
- 77.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TGF-beta signaling, colorectal cancer metastasis, immune evasion, T-cell exclusion, tumor microenvironment, immune checkpoint inhibitors, TGF-beta inhibition, liver metastasis, microsatellite stable colorectal cancer, genetically engineered mouse models, organoid transplantation, combination immunotherapy
- MeSH terms
- Alleles, Animals, Cell Differentiation, Colonic Neoplasms, Disease Models, Animal, Drug Synergism, Female, Humans, Immunotherapy, Intestinal Mucosa, Intestines, Liver Neoplasms, Male, Mutation, Neoplasm Metastasis, Stem Cells, T-Lymphocytes, Cytotoxic, Transforming Growth Factor beta, Th1 Cells, Mice, Immune Evasion, Tumor Microenvironment, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.